Del Carmen Jeffrey's Form 4 filing
Catalyst Pharmaceuticals, Inc. (CPRX) · filed Nov 15, 2022
- Accession no.
- 0001161697-22-000547
- Filed
- Nov 15, 2022
- Trade date
- Nov 11, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.24M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Del Carmen JeffreyCIK 0001816477 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2022 | Common stock, par value $0.001 per share | MOption exerciseAcquired | +120,000 | $2.86 | +$343,200 | 120,000 | Direct | |
| Nov 11, 2022 | Common stock, par value $0.001 per share | SSaleDisposed | −120,000 | $16.23F2 | −$1,947,600 | 0 | Direct | |
| Nov 11, 2022 | Common stock, par value $0.001 per share | MOption exerciseAcquired | +19,017 | $2.24 | +$42,598.08 | 19,017 | Direct | |
| Nov 11, 2022 | Common stock, par value $0.001 per share | SSaleDisposed | −19,017 | $15.46F3 | −$294,002.82 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2022 | Common Stock | MOption exerciseDisposed | −120,000 | $0.00 | $0 | 627,000 | Direct | |
| Nov 11, 2022 | Common Stock | MOption exerciseDisposed | −19,017 | $0.00 | $0 | 607,983 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Shares were sold in various lots from $15.87 to $16.44 per share. The price listed represents a weighted average price for the shares sold.
Referenced by the price of 1 transaction in Table I.
- F3
Shares were sold in various lots from $15.25 to $15.78 per share. The price listed represents a weighted average price for the shares sold.
Referenced by the price of 1 transaction in Table I.